• Internal medicine · Dec 2024

    Prediagnostic Phase of Progressive Supranuclear Palsy in a Longitudinal Epidemiological Study of Dementia and Aging: A Case Report.

    • Kenta Ishii, Hisashi Takahashi, Misaki Kubota-Hanya, Rei Yasuda, Fumitoshi Niwa, Masaki Kondo, and Toshiki Mizuno.
    • Department of Neurology, North Medical Center, Kyoto Prefectural University of Medicine, Japan.
    • Intern. Med. 2024 Dec 19.

    AbstractA 63-year-old previously healthy man participated in a longitudinal epidemiologic study of dementia and aging. Although he initially showed no subjective symptoms and a normal motor function, verbal fluency test scores gradually declined, and progressive atrophy of the frontal lobes was observed on magnetic resonance imaging of the head. At 71 years old, progressive supranuclear palsy (PSP) was diagnosed after supranuclear gaze palsy, and gait disturbance developed. This longitudinal epidemiological study suggests that verbal symptoms and mild frontal lobe atrophy may be evident in the premotor phase of PSP.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.